Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119558 · ClinicalTrials.gov registry record · Early Phase 1
PET/MRI Evaluation of Cardiac Amyloid
A Early Phase 1 study of Cardiac Amyloidosis, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03119558 is a Early Phase 1 study of Cardiac Amyloidosis that has completed, run by Stanford University. The registered enrollment target is 9 participants, below the 954-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03119558, a Early Phase 1 study of Cardiac Amyloidosis, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.
Conditions Studied
Interventions
- DRUG 18F-Florbetaben (Neuraceq®) PET/MRI
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-05-26 |
| Est. Completion | 2018-08-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03119558
The ClinicalTrials.gov registry entry for NCT03119558 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 954-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (99% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which 18F-Florbetaben (Neuraceq®) PET/MRI is the first listed.
NCT03119558 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03119558 about?
NCT03119558 is a clinical study titled "PET/MRI Evaluation of Cardiac Amyloid". Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid c...
What is the current status of trial NCT03119558?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2016-05-26. Estimated completion is 2018-08-28.
What conditions does trial NCT03119558 study?
This clinical trial studies the following conditions: Cardiac Amyloidosis.
What interventions are being tested in trial NCT03119558?
The interventions under investigation include: 18F-Florbetaben (Neuraceq®) PET/MRI (DRUG).
Who is sponsoring clinical trial NCT03119558?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03119558 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
RECRUITING · NA
-
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
RECRUITING
-
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RECRUITING
-
US Benchmarking Clinical Study
RECRUITING
-
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.